Each film-coated tablet contains Dapagliflozin Propanediol Monohydrate equivalent to Dapagliflozin 10 mg + Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 100 mg + Metformin Hydrochloride SR 1000 mg.

Sitanorm DM Tablets combine three complementary antidiabetic agents—Dapagliflozin (SGLT2 inhibitor), Sitagliptin (DPP-4 inhibitor), and Sustained-Release Metformin (biguanide)—to provide comprehensive glycaemic control in adults with type 2 diabetes mellitus. Dapagliflozin promotes urinary glucose excretion, Sitagliptin enhances glucose-dependent insulin secretion and suppresses glucagon release, while Metformin reduces hepatic glucose production and improves insulin sensitivity. The triple-drug combination helps achieve better glycaemic control when diet, exercise, and dual therapy are insufficient.

Sitanorm DM Tablets are indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.

Dapagliflozin inhibits sodium-glucose co-transporter-2 (SGLT2), reducing renal glucose reabsorption and increasing urinary glucose excretion. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs the action of incretin hormones, increasing glucose-dependent insulin release and decreasing glucagon secretion. Metformin is an antihyperglycaemic agent that lowers hepatic glucose production, decreases intestinal glucose absorption, and enhances peripheral insulin sensitivity, thereby reducing both fasting and postprandial blood glucose levels.

The recommended dosage is one tablet orally once daily with food, or as directed by the physician.

Sitanorm DM Tablets are contraindicated in patients with a history of serious hypersensitivity reactions to dapagliflozin, sitagliptin, metformin, or any component of the formulation. It is also contraindicated in patients with metabolic acidosis, including diabetic ketoacidosis.